Dogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due November

Dogwood Therapeutics (DWTX) completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, with 239 patients enrolled, reaching the upper end of its target.